Partners News Xenikos enrolls first patient in global pivotal phase 3 study evaluating T-Guard
30 June 2022

This week, Xenikos announced the first patient dosed in their Phase 3 study for T-Guard, a candidate for the treatment of severe acute graft-versus-host disease (aGVHD). 

Learn more in their press release.

Related news items


Simmunext: where immunotherapy and chemistry meet

2 June 2022 The story behind Radboud university medical center’s, Radboud University’s and Oncode’s newest spinoff, Simmunext Biotherapeutics B.V. read more

T-Guard can reset immune system

1 December 2021 For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard. read more

BIOTRIP vision for biotech incubator

9 November 2021 BIOTRIP, the biotech incubator, presents its vision. read more

Teaming up to develop an effective cure for mycobacterium abscessus disease using inhaled tigecycline

7 July 2021 PureIMS, Radboudumc, and Sever Pharma Solutions are now teaming up to develop an effective cure for this chronic and debilitating disease. read more

Radboudumc and Eindhoven University of Technology join forces in BIOTRIP Biotech incubator to deliver the vaccines and immunotherapies of the future.

1 July 2021 BIOTRIP is a unique platform aimed at developing, commercializing, and making available of vaccins and immunotherapies. read more

Radboudumc and Radboud University strengthen collaboration with Janssen

17 March 2019 On March 12, Radboudumc and Radboud University have signed a letter of intent for intensified collaboration with Janssen. read more